Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-30
2006-05-30
Pryor, Alton (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07053100
ABSTRACT:
The use of a 1,3-oxathiolane nucleoside analogue and pharmaceutically acceptable derivatives thereof for the treatment of hepatitis B virus infections is disclosed. Pharmaceutical formulations are also provided.
REFERENCES:
patent: 4724232 (1988-02-01), Rideout et al.
patent: 4874751 (1989-10-01), Beacham et al.
patent: 5041449 (1991-08-01), Belleau et al.
patent: 5047407 (1991-09-01), Belleau et al.
patent: 5059418 (1991-10-01), Soike
patent: 5071983 (1991-12-01), Koszalka et al.
patent: 5151426 (1992-09-01), Belleau et al.
patent: 5204466 (1993-04-01), Liotta et al.
patent: 5210085 (1993-05-01), Liotta et al.
patent: 5486520 (1996-01-01), Belleau et al.
patent: 5538975 (1996-07-01), Dionne
patent: 5618820 (1997-04-01), Dionne
patent: 5728575 (1998-03-01), Liotta et al.
patent: 5814639 (1998-09-01), Liotta et al.
patent: 5827727 (1998-10-01), Liotta et al.
patent: 5892025 (1999-04-01), Liotta et al.
patent: 5914331 (1999-06-01), Liotta et al.
patent: 5914400 (1999-06-01), Liotta et al.
patent: 6812233 (2004-11-01), Liotta
patent: 0 196 185 (1986-10-01), None
patent: 0 206 497 (1986-12-01), None
patent: 0 337 713 (1989-10-01), None
patent: 0 382 519 (1990-08-01), None
patent: 0 382 526 (1990-08-01), None
patent: 0 337 713 (1990-10-01), None
patent: 0 392 791 (1990-10-01), None
patent: 0 494 119 (1992-07-01), None
patent: 0 513 917 (1992-11-01), None
patent: 0 515 144 (1992-11-01), None
patent: 0 515 156 (1992-11-01), None
patent: WO 91/11186 (1991-08-01), None
patent: WO 92/14743 (1992-09-01), None
patent: WO 92/18517 (1993-10-01), None
Antiviral Research, 17(Suppl. 1):1 (3 pages), (Mar. 1992), providing abstracts from the Fifth International Conference on Antiviral Research. Vancouver, B.C., Canada, Mar. 8-13, 1992.
Virology(Part 1), 5thInternational AIDS Congress, Jun. 1989.
Averett, D.R., “Anti-HIV Compound assessment by two novel high capacity assays,”J. Virol. Methods, 23(3):263-276 (Mar. 1989).
Beach, J. W., et al., “Synthesis of (−)-L-beta-BCH from L-glucose and its anti-HIV and anti-HBV activity,”Abstracts of Papers from the 203rdACS National Meeting, 203(1-3), #50 (1992).
Beach, J.W., et al., “Synthesis of Enantiomerically Pure (2′R,5′S)-(1)-1-[2-hydroxymethyl)-oxatiolan-5-yl] Cytosine as a Potent Antiviral Agent Against Hepatitis B Virus (HBV) and Human Immunodeficiency Virus (HIV),”J. Org. Chem., 57:2217-2219 (1992).
Belleau, B., et al.,Chem. Abstr. 114:43492b (1991).
Choi, W.-B., et al., “Synthesis, Anti-Human Immunodeficiency Virus, and Anti-Hepatitis B Virus Activity of Pyrimidine Oxathiolane Nucleosides,”Bioorgan. and Med. Chem. Lett., 3(4):693-696 (1993).
Choi, W.-B., et al, “In Situ Complexation Directs the Stereochemistry of N-Glycosylation in the Synthesis of Oxathiolanyl and Dioxolanyl Nucleoside Analogues,”J. Am. Chem. Soc., 113(24):9377-9379 (1991).
Divaker, K., and Reese, C.,J. Chem. Soc., Perkins Trans. I, 1982:1171 (1982).
Doong, S.-L., et al., “Inhibition of the replication of hepatitis B virus in vitro by 2',3'-thiacytidine and related analogues,”Abstracts of the ICAAC, p. 181, Abstract No. 496 (Aug. 9, 1991).
Doong, S.-L., et al., “Inhibition of the Replication of Hepatitis B Virusin vitroby 2',3'-Dideoxy-3'-Thiacytidine and Related Analogues,”Proc. Natl. Acad. Sci. USA, 88:8495-8499 (Oct. 1991).
Doong, S.-L., et al.,Chem. Abstr. 115:269987z (1991).
Duschinsky, R.,Nuvleic Acid Chemistry, Part I, J. Wiley & Sons, New York, 43-46 (1978).
Elion, G.B., et al., “Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemi-cally related antimetabolites,”J. Biol. Chem., 208(2):477-488 (Jun. 1954).
Greenberg, S.B., et al., “Metabolism, toxicity and anti-HIV activity of 2'-deoxy-3'-thia-cytidine (BCH-189) in T and B cell lines,”Annals of the New York Academy of Sciences, 616:517-518 (1990).
Hallongquist, E.G., et al.,Can. J. Research, 8:129 (1933).
Hesse, G., and Jorder, I.,Chem. Ber., 85:924-932 (1952).
Kassianides, C., et al., “Effects of 2',3'-dideoxycytidine on duck hepatitis B virus,”Gastroenterology94(5, part 2):A552 (1988).
Liotta, D.C., et al.,Chem. Abstr. 115:208463d (1991).
Matthes, E., et al., “Potent Inhibition of Hepatitis B Virus Production In Vitro by Modified Pyrimidine Nucleosides,”Antimicrobial Agents and Chemotherapy, 34(10):1986-1990.
McCollum, R.W.,Viral Hepatitis, Chapter 12, pp. 327-350.
Miller, R.H., et al., “Common Evolutionary Origin of Hepatitis B Virus and Retrovirus,”Proc. Natl. Acad. Sci. USA, 83:2531-2535 (1986).
Norbeck, D., et al., “A New 2',3'-Dideoxynucleoside Prototype with In Vitro Activity Against HIV,”Tetrahedron Lett., 30(46):6263-6266 (1989).
Robbins, M.J., et al.,Nucleic Acid Chemistry, Part 2, J. Wiley & Sons, New York, 895-900 (1978).
Schinazi, R.F., et al.,Chem. Abstr. 115:174631q (1991).
Schleicher and Schuell, S&S, 10 Optical Ave., Keene, NH 03431, Publication No. 700, 1987.
Sells, M.A., et al, “Production of Hepatitis B Virus Particles in Hep G2 Cells Transfected with Cloned Hepatitis B Virus DNA,”Proc. Natl. Acad Sci. USA, 84:1005-1009 (1987).
Sells, M.A., et al., “Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions,”J. Virol., 62(8):2836-2844 (Aug. 1988).
Soike et al.,Chem. Abstr. 115:174635u (1991).
Soudeyns, H., et al., “Anti-Human Immunodeficiency Virus Type 1 Activity and In Vitro Toxicity of 2'-Deoxy-3'-Thiacytidine (BCH- 189), a Noval Heterocyclic Nucleoside Analog,”Antimicrobial Agents and Chemotherapy, 35(7): 1386-1390 (Jul. 1991).
Southern, E.M., “Detection of specific sequences among DNA fragments separated by gel electrophore-sis,”J. Mol. Biol., 98(3):503-517 (Nov. 5, 1975).
Sung, W.L., “Synthesis of 4-triazolopyrimidinone nucleotide and its application in synthesis of 5-methylcy-tosine-containing oligodeoxyribonucleotides”Nucleic Acids Res., 9(22):6139-6151 (Nov. 25, 1981).
Tyle, P.,Pharmaceutical Research, 3(6):318-326 (1986).
Emory University, Inc.
King & Spalding LLP
Knowles, Esq. Sherry M.
Pryor Alton
LandOfFree
Therapeutic nucleosides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic nucleosides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic nucleosides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3571350